Bliss GVS Pharma (506197) Q4 10/11 earnings summary

Executive summary

• FY11 operations strengthened: net sales rose to Rs 21,883.81 lakh from Rs 16,887.53 lakh; profit before tax increased, while profit after tax declined. [document source 6, 21]

• Expansion included a herbal lozenges plant in Nairobi, a Singapore export subsidiary and a Kuwait manufacturing joint venture. [document source 6]

Financial highlights

• Total income was Rs 22,071.07 lakh vs Rs 17,112.39 lakh; net sales were Rs 21,883.81 lakh vs Rs 16,887.53 lakh. [document source 6, 21]

• Profit before tax was Rs 5,298.14 lakh vs Rs 4,575.52 lakh; profit after tax was Rs 4,063.03 lakh vs Rs 4,172.15 lakh. [document source 6, 21]

• Total expenditure was Rs 16,772.93 lakh vs Rs 12,536.87 lakh. [document source 21]

Outlook and guidance

• Planned overseas local manufacturing units and joint ventures to support business expansion; Kuwait JV targets suppositories and other pharmaceutical products. [document source 6, 16]

• Productivity initiatives targeted higher manufacturing yield and lower costs; recovery actions on old dues included legal cases. [document source 16]